Adia Nutrition Promotes Emmanuela Derisbrun, APRN, FNP-C, to Provider Role Amid Growing Patient Demand and Launch of Autism IRB Study
Rhea-AI Summary
Adia Nutrition (OTCQB: ADIA) announced that Emmanuela Derisbrun, APRN, FNP-C, has moved from subcontractor to employed provider at Adia Med to support rising patient volume and the launch of an IRB-approved autism spectrum disorder regenerative study (NCT07304440). Emmanuela has administered stem cell treatments and therapeutic plasma exchange (TPE) at Adia Med and brings experience in IV vitamin therapies, hormone replacement, thyroid disorders, hypertension, diabetes, sickle cell disease, post-COVID care, and chronic pain management. The company said the hire strengthens clinical capacity as patient demand grows and the autism study begins; contact and study details are provided on ClinicalTrials.gov and Adia Med's website.
Positive
- IRB-approved autism study initiated (NCT07304440)
- Provider role filled to support rising patient volume
Negative
- None.
News Market Reaction
On the day this news was published, ADIA gained 14.50%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Winter Park, Florida--(Newsfile Corp. - January 15, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its medical division Adia Med specializing in advanced regenerative therapies, announces that Emmanuela Derisbrun, APRN, FNP-C, has transitioned from subcontractor to employed provider. This move supports rising patient volume and the launch of Adia Med's IRB-approved autism spectrum disorder regenerative study.
Emmanuela Derisbrun, APRN, FNP-C
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/280518_screenshot_emmy_np_photo_550.jpg
A board-certified Family Nurse Practitioner with extensive outpatient specialty experience, Emmanuela served as a subcontractor at Adia Med for the past year, where she has already administered stem cell treatments and therapeutic plasma exchange (TPE) while delivering evidence-based, patient-centered care under strict clinical and safety protocols.
Her background includes IV vitamin therapies and management of hormone replacement, thyroid disorders, hypertension, diabetes, sickle cell disease, post-COVID conditions, and chronic pain. She collaborates in multidisciplinary teams to ensure high-quality care, accurate documentation, and positive patient outcomes.
Committed to education, informed consent, and safety, Emmanuela is expanding her work in investigational therapies, including the autism IRB study, as part of her professional growth in regenerative medicine.
"Emmanuela has been invaluable-already contributing to stem cell and TPE treatments-and her transition strengthens our team as demand grows and our autism study begins," said Larry Powalisz, CEO of Adia Nutrition.
Emmanuela added: "I'm excited to deepen my role at Adia Med, advancing regenerative care and supporting better patient outcomes through compassion and excellence."
For more information on Adia Med's services or to schedule a consultation, visit www.adiamed.com.
To learn more about the autism IRB study, see view the full details on ClinicalTrials.gov here: Study Details | NCT07304440 | Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study | ClinicalTrials.gov
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280518
FAQ
Who is Emmanuela Derisbrun and what is her new role at Adia Nutrition (ADIA)?
What does the IRB-approved autism study (NCT07304440) announced by ADIA cover?
How does ADIA say the hiring affects patient care and operations?
What treatments has Emmanuela Derisbrun provided at Adia Med before her hire?
How can patients or clinicians learn more or schedule a consultation with Adia Med (ADIA)?
Where can investors find details about the ADIA autism study timeline and enrollment?
